Ever since the inception of kidney transplant programs the short-term patient and graft survival results have improved progressively, principally because of better management of acute rejection episodes and decreased mortality from infectious complications. However, the rate of annual graft attrition after the first post-transplant year has virtually remained unchanged [1, 2] . About half to three quarters of the late graft losses are explained by patient death with a functioning transplant, mainly as a result of cardiovascular causes, while chronic rejection accounts for 50 to 80% of graft failures in surviving recipients. The estimated graft loss from chronic rejection varies between 4 and 40% in the initial five post-transplant years [3] .
transplant interstitial renal disease [12] . Immune-cytochemistry of rat renal transplants with chronic rejection have drawn attention to an unique population of CD45RC-positive cells in the graft interstitium [13] . CD45RC is one of the restricted epitopes of the CD45 Leukocyte Common antigen and is expressed on all B cells and most T cells, but as most of the graft invading CD45RC-positive cells were negative for lymphocyte or monocyte markers, it was postulated that these cells represent a CD8-negative subpopulation of natural killer cells. We found a novel population of macrophage-derived multinucleated giant cells in the interstitium of rat transplants with chronic rejection [14] . It is presently not known whether these cell types are truly specific for chronic rejection and whether such cell types are also present in human transplants with chronic rejection. Virtually all long-surviving There is widening of subendothelial zones by electron lucent material and interposition of mesangial matrix and cells, giving a double contour appearance to most capillary walls. Immunofiuorescence shows in most cases unspecific segmental deposits of 1gM and fibrin, sometimes associated with trace amounts of C3, but some cases have been described with linear deposits of IgG along the glomerular basement membrane (GBM) or with small peripheral granular deposits of IgG or IgA [28] . The late picture of transplant glomerulopathy consists of enlarged glomeruli with widespread reduplication of the GBM, resembling membranoproliferative glomerulonephritis [28] , There is in later stages mild hypercellularity and many glomeruli show a spongy appearance of expanded mesangial areas containing swollen mesangial cells embedded in matrix material. Slight or moderate epithelial cell proliferation may be present, typically near adhesions between the capillary tuft and Bowman's capsule. Electron microscopy may furthermore show abnormal structures in the basement membrane, between the basement membrane and the endothelium or epithelium, and in the mesangial matrix [23, 29] . Immune histochemistry with antibodies against extracellular matrix proteins has shown peripheral glomerular expansion of collagen type IV and fibronectin [30] . Transplant glomerulopathy is found in 7% of biopsy specimens, representing 23% of all glomerular lesions present in renal allografts [28] and is almost always associated with obliterative vascular lesions [31] .
Any of above histologic features in combination with impaired function or proteinuria is consistent with chronic rejection after exclusion of obvious other causes [6] . However, prospective biopsy studies of transplants with normal or slightly increased serum creatinine levels in the initial two years have shown that up to 2/3 of grafts have some degree of interstitial fibrosis and tubular atrophy and that more than 1/3 have some degree of glomerular sclerosis and intimal proliferation. Although the extent of the lesions is usually mild in the absence of clinical dysfunction [32, 33] , the etiology of the lesions remains to be established.
Risk factors of chronic rejection
Several clinical factors are associated with late allograft failure, as reviewed recently [34] . HLA identical sibling transplants in the UNOS Registry have a half-life, the time it takes for 50% of transplants that function at one year to fail, of more than 20 years compared with less than 10 years in one haplotype mismatched, sibling transplants and seven to eight years in completely mismatched cadaveric donor transplants [35] . These data suggest that the degree of HLA matching has an important effect on long-term graft survival. However, living-related donors usually have short ischemia times and are, for the most part, either HLA-identical or mismatched for a single haplotype. The Eurotransplant data show that matching for both HLA class I and II antigens has a strongly beneficial effect on the long-term graft survival: zero mismatched cadaveric transplants have a 79% five year survival and a half-life of 13.2 years compared with 51% and 7.8 years, respectively, in completely mismatched combinations [36] ; similar data have been reported by the Collaborative Transplant Study Group [37] . It is of interest that the UNOS data show only a long-term matching effect for HLA class I but not class II antigens [38] .
HLA matched and mismatched combinations experience the same degree of early graft loss when acute rejection episodes occur but there is a pronounced split in survival rates beyond the first few months between matched and mismatched combinations whose grafts survived the early rejection episodes, with an obvious acceleration in graft loss among the mismatched group [39] . This suggests that if early rejection episodes initiate late allograft loss, its development may be dependent on HLA incompatibilities.
Furthermore, panel-reactive antibody status has no effect on early graft outcome in HLA-identical transplants but high panelreactivity is associated with a decline in half-life in both matched and unmatched recipients, suggesting that previous allosensitization affects long-term outcome, irrespective of the degree of matching [39] .
More important than matching per se is whether tissue incompatibilities lead to rejection episodes [2, [39] [40] [41] . One study showed that the average half-life decreases from 12.8 2 years for grafts with no rejection episodes to six years or less for grafts with multiple acute rejection episodes [41] . Although not all late graft losses are explained by chronic rejection, multivariate analysis have shown that acute rejection episodes are the strongest risk factor for the development of biopsy-proven chronic rejection [3] .
However, a recently published study from Finland found no correlation between acute and chronic rejection [42] . The authors attributed this lack of correlation to the very low incidence of acute rejection episodes which were usually mild in their particular patient population. The possibility that late graft dysfunction or chronic rejection emerges from inadequate immunosuppression because of concerns of cyclosporine A-mediated nephrotoxic side effects [43] or patient non-compliance [44] has been raised but needs further study. Additional factors associated with late allograft loss include pretransplant hyperlipidemia [45] , long cold ischemia times [46] , delayed graft function [47, 48] , post-transplant infections [3] , donor age [49, 50] , female gender or race of the donor [49] , and recipient obesity [51] . Studies of cardiac transplant patients have furthermore shown a correlation between post-transplant eytomegalovirus (CMV) infection and the development of graft atherosclerosis [52] . Although CMV infections in renal transplant patients have been associated with a specific glomerular lesion postulated to evolve into transplant glomerulopathy [53, 54] , later studies have failed to confirm this relationship [55] .
Hypothesis to explain the immunological or "antigendependent" basis of chronic rejection
As rejection is defined as the clinical and histopathological expression of an allogeneic immune response of the recipient against incompatible transplantation antigens of the graft, it is essential to define the immunological basis of chronic rejection. CD4-positive T lymphocytes play a central role in the regulation of the immune response as they interact with antigen presenting cells, precursor cytotoxic T cells, maerophages, and B cells to coordinate the response. Much of their function is controlled by cytokines, small protein molecules whose expression and secretion is induced as a result of antigen-stimulated cell activation. Longterm clones of murine CD4-positive T cells tend to produce either interleukin-2 (IL-2), interferon gamma (IFN-'y) and tumor necrosis factor beta (TNF-/3), or IL-4, IL-5, IL-6, IL-b, and IL-13 as their unique cytokine products [56] [57] [58] . The former clones have been designated as being of the T helper 1 (TH1) type, and the latter, the TH2 type. The TH1 clones, through their production of IFN-y and TNF-j3 are well suited to induce macrophage-mediated delayed-type hypersensitivity reactions and cytotoxic T cell activity while the T2 clones make products that are well adapted to act in helping B cells develop into antibody-producing cells [57] . The cytokines play a dual role in the differentiation process of the TH1 or TH2 phenotypes; they induce CD4-positive T cells to differentiate into either T1-or T2-like cells while they inhibit the differentiation of the antithetical phenotype [58] . For example, IL-4 is essential for in vitro priming for IL-4 producing cells while it blocks the priming of precursor TH cells to develop into INF-y producers, that is, TH1-like cells [59] . IL-12 enhances but is not essential for the priming of INF-y producing cells [59] . Although most work on TH1ITH2 phenotypic distinctions has been done in murine infectious disease models and initial studies of human CD4-positive T cell clones failed to show the same degree of divergence of cytokine production as observed with murine clones, more recent experiments with antigen-specific T cell clones have shown a greater degree of TH1/Tfl2 polarization in human lymphokine-producing phenotypes than observed initially [60] .
Recent data suggest that cytokines, like INF-y and IL-4, elaborated by CD8-positive cells may also regulate the CD4-positive cells [60, 61] . Furthermore, renal parenchymal cells subjected to ischemia produce an array of cytokines including the TH1-like cytokine INF-y and the TH2-like cytokines IL-6 and IL-b [62, 63] . Graft antigenic epitopes in conjunction with locally produced cytokines elaborated by graft invading cells and renal parenchymal cells as well as recipient prohormone and hormone levels [64] may participate in the regulation of the T phenotypic differentiation of graft invading CD4-positive cells.
Several hypothesis have been proposed to explain the immunological basis of chronic rejection. Chronic rejection could be the final result of recurrent episodes of acute rejections, that is, TH1 orchestrated cytotoxic T cell and macrophage-mediated tissue damage [65] . Recurrent episodes of acute rejection, each treated with immunosuppressive drugs, could persist as a smoldering, chronic process that leads to protracted tissue damage and scarring. Consistent with this hypothesis are clinical studies that have shown that freedom from acute rejection episodes is associated with an excellent long-term graft outcome [66, 67] , although some transplants develop chronic rejection without previous acute rejection episodes [42] . Since routine biopsies often show focal areas of cellular infiltration and inflammation [11, 33, 68] , many of which are CD4-positive, it is conceivable that they represent a population of TH1-like cells, directing localized acute rejection which initially remains limited because of the subsequent local activation of TH2-like cells that release cytokines like IL-4 and IL-b. These cytokines inhibit the generation and activation of T cells that direct pro-inflammatory responses, as discussed, and inhibit the release of IL-i, IL-6 and TNF-cr by cells of the monocyte lineage, and thus limit the rejection reaction. Repeated episodes of such subclinical rejection episodes could lead to low grade, chronic and progressive tissue damage [65] .
An alternative but not mutually exclusive hypothesis to explain chronic rejection is that the immune-regulatory mechanisms that come into action to prevent acute rejection play a role in chronic rejection. As inhibition of T1-like responses by immunosuppressive drugs or biological manipulations like blood transfusions may lead to an ascendency of TH2-like cells, which inhibit THI-like responses but support B cell responses and antibody formation, chronic rejection may be a predominantly antibody-mediated form of graft damage [69] .
The vascular lesions of chronic rejection may thus result from chronic or repeated episodes of TH1-directed acute rejection or TH2-orchestrated antibody-mediated damage against donor transplantation antigens of the graft vessel wall, especially the endothelium [70] . In vitro and in vivo studies have shown that endothelial cells may serve as target cells for allogeneic cellular and humoral effector mechanisms [71] [72] [73] [74] . A recent histopathological study of transplants with clinical evidence of acute rejection has shown that early vascular rejection is strongly correlated with late graft loss; the five year graft survival rate in this group was 34% versus 70 to 75% in patients who have never experienced an acute rejection episode or who had only interstitial rejection in the biopsy taken during the acute rejection episode.' Of interest is a similar study in cardiac transplant patients that showed that grafts with early vascular rejection lesions are more likely to develop graft atherosclerosis than grafts that undergo early interstitial rejection episodes [75] . Although acute rejection-associated vasculitis may result from both cellular [73] An experimental study of rat renal transplants with chronic rejection and transplant glomerulopathy in animals tolerant to donor class I MHC antigens have shown that such recipients mount an 1gM antibody response against endothelial cell-specific alloantigens. Based on immunostaining of tissue specimens, it was postulated that antibodies against glomerular endothelial cell specific antigens are involved in the development of the glomerular lesions [78] . We recently found circulating IgG antibodies against a novel set of donor and third party GBM and TBM antigens in the post-transplant sera from non-immunosuppressed rats with chronic renal allograft rejection, but the pathogenetic significance of the antibodies remains to be established [79] . Thus the nature and specificity of the immune response involved in transplant glomerulopathy remains to be established. Antigen independent factors that influence tissue remodeling post-transplantation There is growing evidence that non-immune or antigen independent factors play a role in the late outcome of kidney transplantation. As discussed, registry data indicate that grafts from very young, elderly, black or female donors survive less well than grafts from donors aged 15 to 55, non-black donors or male donors, with a difference in three-year graft survival between 5 and 20% [49] . It has furthermore been shown that the long-term graft survival is decreased in overweight recipients [51J. Increased graft loss from very young donors could represent technical problems with relatively small renal arteries that do not increase in caliber with increasing renal size or a disadvantaged effect of a rapid increase in growth in these initially small kidneys placed in an adult recipient [83] , while the decreased long-term survival of kidneys from elderly donors could reflect a normal aging-related reduction in renal mass [84] . Furthermore, difficulties in dosing of immunosuppressive medication in obese patients could explain the decreased long-term graft survival in these patients. However, the poorer long-term survival in these situations could, at least in part, be explained by a mismatch between recipient metabolic demands and graft size, maturity or nephron number. The data are consistent with the hypothesis that a mismatch between recipient metabolic demand and graft renal mass is associated with an increased late graft loss [49] . One recently presented, prospective study showed that the five-year survival rate was more than 20% lower in recipients with a low graft mass over recipient body mass ratio compared with combinations with a high graft mass over body weight ratio [851.
Loss of renal mass leads to an increase in size and function of the remaining nephrons and includes an increase in glomerular capillary blood flow and pressure [861, increased glomerular permeability characteristics [87] , glomerular hypertrophy [88] , changes in renal metabolism [89, 90] and lipoprotein disorders secondary to uremia and proteinuria [91] . Generally, these Two clinical studies have found a correlation between the presence of systemic hypertension and an accelerated rate of deterioration of graft function in chronic rejection [96, 97] , but no data are available that demonstrate improved outcome with strict blood pressure control [98] . Dietary protein restriction, an intervention that lowers the glomerular capillary pressure but not the systemic blood pressure under experimental conditions [94] , improves the abnormal permselectivity characteristics of transplants with chronic rejection [99] , and two small clinical studies suggested some benefit of such diets on the rate of progression of renal failure in chronic rejection [100, 101] .
We recently demonstrated in rats that the glomerular capillary pressure increases following unilateral nephrectomy in some strains but not in others [102] . Measurements of glomerular capillary pressures in transplanted kidneys furthermore showed that the capillary pressure in transplanted kidneys resembles that of the donor strain as observed after renal ablation [102, 103] .
Lowering of the glomerular capillary pressure with anti-hypertensive drugs improves graft survival rate, decreases the amount of proteinuria and is associated with preservation of the glomerular structure, while little or no effect was found on the extra-glomerular lesions [104] . Pretranspiant hyperlipidemia is a risk factor for late allograft loss [45] . Low-density lipoprotein is directly toxic to endothelial cells and elevated cholesterol concentrations and hyperlipidemia foster vascular injury, atherosclerosis and glomerulosclerosis [91] .
Experimental studies of cardiac transplants have shown that hypercholesterolemia acts synergistically with allogeneic immune reactions in the development of graft atherosclerosis [106] , but two clinical studies of renal transplant patients have failed to establish a correlation between post-transplant hyperlipidemia and late graft loss [97, 107] . One recent study found that renal transplant patients with chronic vascular rejection had higher VLDL, LDL, total cholesterol and triglyceride levels, more triglyceride-rich VLDL and LDL fractions, and a more atherogenic distribution of the lipoproteins compared with controls [108] .
Although impaired renal function and proteinuria may cause lipid abnormalities, the presence of similar abnormalities in cardiac transplant patients with graft atherosclerosis [1091 supports the hypothesis that the hyperlipoproteinemia contributes to the development of graft atherosclerosis. This possibility is further justified by the presence of apolipoproteins Al, A2 and Bi in the graft vessel wall of human renal allografts with chronic rejection [110] .
Prolonged graft ischemia and delayed graft function are associated with decreased short-and long-term graft survival [47, 48] , but the mechanism underlying these observations remains unknown. Whether specific structural lesions underlie the late decline in function that occurs in grafts exposed to long episodes of graft ischemia is uncertain. Although chronic rejection and ischemia may both result in interstitial fibrosis and increases in glomerular matrix, GBM abnormalities or vascular lesions as observed in chronic rejection are not found in ischemia [1111. Furthermore, the greater impact of ischemia on an allograft compared with a syngeneic graft argues for an interaction between ischemia and immune responsiveness. Ischemia results in increased tissue levels of pro-inflammatory mediators, including cytokines [112, 113] and products of arachidonic acid metabolism [114] , which up-regulate CD1 1/CD 1 8 expression on leukocytes, increase ICAM-1 and MHC expression on endothelial cells, and increase CD11/CD18 avidity for ICAM-1 [115, 116] . As a result, there is increased adherence of leukocytes to endothelial cells, activation of leukocytes, and increased production of additional inflammatory mediators. The up-regulation of incompatible transplantation antigens, cell adhesion molecules and cytokines may increase the immunogenicity and susceptibility of transplanted organs to allogeneic immune reactions, and may explain excessive graft loss from acute rejections of kidneys exposed to long ischemic periods. It is difficult, however, to explain the association of ischemia with chronic rejection. Although anti-ICAM-1 monoclonal antibodies protect the kidney against ischemic renal failure [117] , it is not known whether they protect against ischemiarelated chronic rejection. It is of interest that the degree of vascular and glomerular lesions in experimental renal allografts with chronic rejection correlates with the duration of the perioperative ischemia, while there is no correlation with the degree and extent of cellular inflammation shortly after transplantation [111] .
Growth factors and other mediators of tissue remodeling
Antigen-dependent and antigen-independent mechanisms may control tissue remodeling through the local production of growth factors that influence cell migration and proliferation as well as extracellular matrix metabolism. Growth factors are like cytokines, peptide molecules produced by a variety of cells in response to a range of stimuli, that bind to their receptors on the cell surface followed by activation of intracellular signal transduction pathways and nuclear transcription factors. The same peptide can have both stimulatory and inhibitory activities in a single cell in vitro, depending on the differentiation state of the cell and the presence of other growth factors [1181. Therefore, the combination of growth factors and cytokines, rather than the presence of one particular growth factor, is the most important determinant for a given biological response of the cells exposed to them.
Immunological mechanisms like acute rejection reactions [119] , as well as antigen-independent mechanisms like ischemia [62, 63] , glomerular hypertension [120] , and lipid deposits [1211 stimulate the release of various cytokines and growth factors from lymphoid cells [56, 57] , macrophages [122] , natural killer cells [123] , vascular wall cells [121] and renal parenchymal cells [63, 124] . The cytokines and growth factors, in turn, may regulate the proliferation and metabolic activities of the graft infiltrating cells as well as the graft cells themselves [121, 123] .
Atherosclerotic vessel wall remodeling in response to vascular injury is an example of a predominantly growth factor-driven lesion [121, 125] . It was originally proposed that loss of endothehal cell lining results in the formation of platelet thrombi that adhere to the subendothelium, followed by the release of growth regulating factors, like platelet-derived growth factor (PDGF). Proteases and elastases released from the vessel wall or vessel wall-invading inflammatory cells may cause degradation of extracellular matrix and release of growth factors that have been stored in an inactive form bound to the extracellular matrix [126, 127] .
However, it is now recognized that atherosclerosis may also develop without loss of endothelial cell lining or obvious endothehial cell damage [128, 129] . Endothelial and smooth muscle cells may become "activated" during vessel wall injury and produce a myriad of multifunctional cytokines and growth factors, while graft wall invading T and B lymphocytes, macrophages, and NK cells may be additional sources of growth factors and cytokines when appropriately stimulated [58, 122, 123] . As mesangial cells have many features in common with vascular smooth muscle cells, it has been proposed that the processes that cause atherosclerosis in vessels cause mesangial sclerosis in the glomeruhi [130] .
Transplants with acute or chronic rejection have increased levels of PDGF receptor and ligand mRNA and proteins in the Transforming growth factor-f3 (TGF-/3), a polypeptide growth factor produced by a large number of different cell types, including monocytes, macrophages, neutrophils, T lymphocytes, B lymphocytes and glomerular cells [80, 135, 136] , has potent immunosuppressive properties [136] [137] [138] , induces epithehial cells to synthesize fibronectin and stimulates cultured mesangial and glomerular epithelial cells to produce decorin and biglycan [82] .
Enhanced extracellular matrix formation in conjunction with decreased matrix degradation, results in increased net deposition of extra cellular matrix material and fibrosis [135] . Sustained renal expression of TGF-p has indeed been shown to be associated with progressive fibrosis [82] . Northern blots have shown up-regulation of TGF-f3 mRNA in allogeneic rat kidney grafts with or without clinical or histological evidence of rejection [131] , and quantitative measurements of TGF-J3 transcripts in human renal transplant biopsies have demonstrated a correlation between TGF-f3 mRNA levels and interstitial fibrosis [139] . The interstitial accumulation of cellular derived fibronectin and tenascin, glycoproteins involved in architectural tissue remodeling, in acute and chronic rejection has been attributed to the local TGF-f3 production [140] .
IL-6 is a mitogen for smooth muscle and mesangial cells [141] , although it inhibited mesangial cell growth in one study [142] .
Human renal allografts have increased levels of IL-6 transcripts in glomerular, tubular, vascular and graft infiltrating cells during acute rejection [143] and immunohistochemistry of rat renal allografts with chronic rejection have shown IL-6 protein in the mesangium and the mononuclear cells that invade the glomeruli [144] .
Of interest are recent studies of experimental cardiac transplants that have shown that soluble tumor necrosis factor receptors or a monoclonal antibody against interferon-y inhibit vascular intimal proliferation [145, 146] . The list of other growth factors and cytokines potentially involved is long and include IL-i, fibroblast growth factors, angiotensin II, and many others as reviewed elsewhere [133] . However, the direct evidence linking chronic rejection to specific cytokines is limited, and the roles of the various mediators and combinations of cytokines and growth factors can only be assessed critically when strategies become available that allow long-term suppression of their production or blocking of their signal transduction pathways.
In addition to vessel wall proliferation in response to locallyproduced growth factors, vascular smooth muscle cells may also proliferate as a result of loss of natural proliferation inhibitors such as the extracellular heparan sulfate proteoglycan matrix. Of interest are studies that have shown that exogenous administration of low molecular weight heparins have a beneficial effect on the vascular lesions of chronic rejection in experimental cardiac transplants [147, 148] .
Summary and conclusions
Chronic rejection results from recurrent episodes of subclinical or clinically evident acute rejection, with or without involvement 
